Surrogate Binding Proteins Cancer Therapy Patent
Summary
The EPO published patent application EP3446707A1 for surrogate binding proteins targeting cancer therapy, filed by RevOpsis Therapeutics, Inc. and RevOpsis Holdings, LLC. The application covers immunotherapy compositions using engineered binding proteins classified under A61K 39/00, A61P 35/00 (cancer), and C07K 16/28, with all EU member states designated.
What changed
The EPO published patent application EP3446707A1 titled "Surrogate Binding Proteins" for RevOpsis Therapeutics, covering engineered binding protein compositions for cancer therapy. The application is classified under IPC codes A61K 39/00, A61P 35/00, and C07K 16/28, with all EU member states designated as covered territories.
Pharmaceutical and biotechnology companies developing bispecific antibody or targeted protein therapeutics should monitor this application for potential freedom-to-operate concerns. Competitors in the immuno-oncology space may need to evaluate whether their R&D programs or pipeline candidates could fall within the scope of RevOpsis's claims upon grant.
What to do next
- Monitor patent register for substantive examination results
- Conduct freedom-to-operate analysis for competing immunotherapy candidates
- Review designated EU states for validation strategy implications
Archived snapshot
Apr 8, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
SURROGATE BINDING PROTEINS
Publication EP3446707A1 Kind: A1 Apr 01, 2026
Applicants
RevOpsis Therapeutics, Inc., RevOpsis Holdings, LLC
Inventors
KASHYAP, Arun K., BHATT, Ramesh R., HOROWITZ, Michael, HOROWITZ, Lawrence, ZHOU, Sihong, O'NEIL, Ryann E., HANNUM, Charles H., KURTZMAN, Aaron L., XU, Li
IPC Classifications
A61K 39/00 20060101AFI20190117BHEP A61P 35/00 20060101ALI20190117BHEP C07K 16/28 20060101ALI20190117BHEP
Designated States
AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR
Related changes
Get daily alerts for ChangeBridge: EPO Bulletin - Therapeutics (A61P)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from EPO.
The plain-English summary, classification, and "what to do next" steps are AI-generated from the original text. Cite the source document, not the AI analysis.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when ChangeBridge: EPO Bulletin - Therapeutics (A61P) publishes new changes.